Skip to main content

Value Stock - Dividend - Research Selection

ISIN: , WKN:

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


La Jolla Pharmaceutical : Statement of Changes in Beneficial Ownership - Form 4

2022-08-24
Ownership Submission FORM 4 Check this box if no longer... | August 24, 2022

Innoviva Completes Acquisition of La Jolla Pharmaceutical

2022-08-22
BURLINGAME, Calif., August 22, 2022--Innoviva, Inc. (Nasdaq: INVA) ("Innoviva"), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of La Jolla Pharmaceutical Company (Nasdaq: LJPC) ("La Jolla") at a price of $6.23 per share (the "Offer Price"), net to the seller in cash, without interest and less required withholding taxes,

La Jolla Pharmaceutical : Termination of a Material Definitive Agreement - Form 8-K

2022-08-22
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ... | August 22, 2022

LA JOLLA PHARMACEUTICAL CO : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)

2022-08-22
Item 1.02 Termination of Material Definitive Agreement.Effective as of August 22, 2022, and immediately following the effective time ofthe Merger , the Company terminated the Company's Amendedand... | August 22, 2022

LA JOLLA PHARMACEUTICAL CO Management's Discussion and Analysis of Financial Condition and Resultsof Operations (form 10-Q)

2022-08-15
You should read the following discussion and analysis of our financial conditionand results of operations together with our condensed consolidated financialstatements and the related notes and... | August 15, 2022